Drug Makers In India Move To Lifestyle Drugs For Income
This article was originally published in PharmAsia News
Indian drug makers are reshaping portfolios in an effort to gain a greater share of lifestyle medicine sales. Among them is Alembic, whose emphasis has been on antibiotic and other acute-therapy drugs, but now moving into an emphasis on cancer, cardiovascular and diabetes drugs. Alembic acquired a non-oncology portfolio from Dabur Pharma last year to give it an entry into that market. Indian drug makers see lifestyle drugs as growing from the current 14 percent to 17 percent of the market by 2010. (Click here for more
You may also be interested in...
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).